Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003 Jul;9(7):1501-3.
doi: 10.3748/wjg.v9.i7.1501.

Interruption of HBV intrauterine transmission: a clinical study

Xiao-Mao Li  1 , Yue-Bo Yang, Hong-Ying Hou, Zhong-Jie Shi, Hui-Min Shen, Ben-Qi Teng, Ai-Min Li, Min-Feng Shi, Ling Zou
Affiliations
Clinical Trial

Interruption of HBV intrauterine transmission: a clinical study

Xiao-Mao Li et al. World J Gastroenterol. 2003 Jul.

Abstract

Aim: To investigate the effect of hepatitis B virus (HBV) specific immunoglobin (HBIG) and lamivudine on HBV intrauterine transmission in HBsAg positive pregnant women.

Methods: Each subject in the HBIG group (56 cases) was given 200 IU HBIG intramuscularly (im.) every 4 weeks from 28-week (wk) of gestation, while each subject in the lamivudine group (43 cases) received 100 mg lamivudine orally (po.) every day from 28-wk of gestation until the 30(th) day after labor. Subjects in the control group (52 cases) received no specific treatment. Blood specimens were tested for HBsAg, HBeAg, and HBV-DNA in all maternities at 28-wk of gestation, before delivery, and in their newborns 24 hours before the administration of immune prophylaxis.

Results: Reductions of HBV DNA in both treatments were significant (P<0.05). The rate of neonatal intrauterine HBV infection was significantly lower in HBIG group (16.1 %) and lamivudine group (16.3 %) compared with control group (32.7 %) (P<0.05), but there was no significant difference between HBIG group and lamivudine group (P>0.05). No side effects were found in all the pregnant women or their newborns.

Conclusion: The risk of HBV intrauterine infection can be effectively reduced by administration of HBIG or Lamivudine in the 3(rd) trimester of HBsAg positive pregnant women.

PubMed Disclaimer

References

    1. Li XM, Liu SL, Li X, Huang HJ, Lu JX, Gao ZL. The level of HBV DNA in peripheral, umbilical, and milk of maternal and its correlation. Zhongshan Yike Daxue Xuebao. 2000;21:233–235.
    1. Merle P, Trépo C, Zoulim F. Current management strategies for hepatitis B in the elderly. Drugs Aging. 2001;18:725–735. - PubMed
    1. Hamdani-Belghiti S, Bouazzaou NL. [Mother-child transmission of hepatitis B virus. State of the problem and prevention] Arch Pediatr. 2000;7:879–882. - PubMed
    1. Zhang SL, Han XB, Yue YF. Relationship between HBV viremia level of pregnant women and intrauterine infection: neated PCR for detection of HBV DNA. World J Gastroenterol. 1998;4:61–63. - PMC - PubMed
    1. Shiraki K. Perinatal transmission of hepatitis B virus and its prevention. J Gastroenterol Hepatol. 2000;15 Suppl:E11–E15. - PubMed

Publication types

MeSH terms